{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:51:08Z","timestamp":1790175068858,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":2194,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1111\/jth.13491","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T21:16:43Z","timestamp":1472851003000},"page":"2095-2106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Advances in the treatment of bleeding disorders"],"prefix":"10.1016","volume":"14","author":[{"given":"F.","family":"Peyvandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garagiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Biguzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13491_bb0010","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(08)60872-7","article-title":"Why rare diseases are an important medical and social issue","volume":"371","author":"Schieppati","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"10.1111\/jth.13491_bb0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2516.2006.01263.x","article-title":"Genetic diagnosis of haemophilia and other inherited bleeding disorders","volume":"12","author":"Peyvandi","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0020","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2013-06-498303","article-title":"Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy","volume":"122","author":"von Lillicrap","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0025","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"Palla","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0030","series-title":"Report on the Annual Global Survey 2014","year":"2015"},{"key":"10.1111\/jth.13491_bb0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1055\/s-0034-1543998","article-title":"Treatment of hemophilia in the near future","volume":"41","author":"Peyvandi","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.13491_bb0040","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2013 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13491_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00402-011-1421-3","article-title":"Chronic ankle instability: diagnosis and treatment","volume":"132","author":"Rodriguez\u2010Merchan","year":"2012","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1111\/jth.13491_bb0050","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1\u2010Deamino\u20108\u2010d\u2010arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands\u2019 diseases","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet"},{"key":"10.1111\/jth.13491_bb0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1111\/jth.13491_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco\u2010Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13491_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2516.2012.02926.x","article-title":"Short\u2010term low\u2010dose secondary prophylaxis for severe\/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi\u2010centre pilot study in China","volume":"19","author":"Tang","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94\u20109027, a PEGylated B\u2010domain\u2010deleted recombinant FVIII with an extended half\u2010life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0075","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first\u2010in\u2010human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0080","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full\u2010length, recombinant factor VIII for prophylactic and on\u2010demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0090","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0049-3848(13)70150-6","article-title":"Innovative coagulation factors: albumin fusion technology and recombinant single\u2010chain factor VIII","volume":"131S2","author":"Schulte","year":"2013","journal-title":"Thromb Res"},{"issue":"Suppl. 2","key":"10.1111\/jth.13491_bb0095","first-page":"19","article-title":"rVIII\u2010Single chain pharmacokinetics in adults, adolescents and children","volume":"22","author":"Mahlangu","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0100","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/blood-2011-02-335596","article-title":"Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B","volume":"118","author":"Negrier","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0105","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl. s3","key":"10.1111\/jth.13491_bb0110","first-page":"94","article-title":"Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B. Abstracts of the WFH 2014 World Congress","volume":"20","author":"Powell","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0115","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX\u2010FP) in hemophilia B patients","volume":"120","author":"Santagostino","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/hae.12721","article-title":"Results of a phase I\/II open\u2010label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients","volume":"21","author":"Martinowitz","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0125","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long acting recombinant coagulation factor IX albumin fusion protein (rIX\u2010FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V126.23.1087.1087","article-title":"Long\u2010term safety and efficacy of rFVIIIFc in adults and adolescents with severe hemophilia A: a longitudinal analysis of A\u2010LONG and ASPIRE. ASH Annual Meeting Abstract","volume":"126","author":"Pasi","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0135","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.13360","article-title":"Role of enhanced half\u2010life factor VIII and IX in the treatment of haemophilia","volume":"169","author":"Mahdi","year":"2015","journal-title":"Br J Haematol"},{"issue":"Suppl. 4","key":"10.1111\/jth.13491_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/hae.12405","article-title":"Changing paradigm of prophylaxis with longer acting factor concentrates","volume":"20","author":"Carcao","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V126.23.1088.1088","article-title":"Extended\u2010interval prophylaxis with rFIXFc in adults and adolescents with hemophilia B: interim results of the B\u2010YOND extension study. ASH Annual Meeting Abstract","volume":"126","author":"Mahlangu","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0150","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/hae.12074","article-title":"Treatment guidelines working group on behalf of The World Federation Of Hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1160\/TH15-10-0780","article-title":"Long\u2010acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A","volume":"116","author":"Mahlangu","year":"2016","journal-title":"Thromb Haemost"},{"issue":"Suppl. S2","key":"10.1111\/jth.13491_bb0160","first-page":"349","volume":"13","author":"Brand","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bjh.13112","article-title":"Long\u2010acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B\u2010LONG study","volume":"168","author":"Powell","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13491_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2516.2002.00587.x","article-title":"Use of recombinant factor IX in subjects with haemophilia B undergoing surgery","volume":"8","author":"Ragni","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0175","first-page":"e196","article-title":"Safety and efficacy of plasma\u2010derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis","volume":"17","author":"Quon","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0180","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jth.12000","article-title":"Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9\u2010GP), a glycoPEGylated recombinant factor IX","volume":"10","author":"Collins","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0185","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12317","article-title":"Hemophilia A and B: focus on arthropathy and variables affecting bleeding severity and prophylaxis","volume":"11","author":"Escobar","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1111\/jth.13491_bb0190","first-page":"843","volume":"13","author":"Negrier","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0195","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1160\/TH07-08-0525","article-title":"Prolonged in\u2010vivo half\u2010life of factor VIIa by fusion to albumin","volume":"99","author":"Weimer","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0200","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1210\/en.2009-1431","article-title":"Designing a long\u2010acting human growth hormone (hGH) by fusing the carboxyl\u2010terminal peptide of human chorionic gonadotropin beta\u2010subunit to the coding sequence of hGH","volume":"151","author":"Fares","year":"2010","journal-title":"Endocrinology"},{"issue":"Suppl. s2","key":"10.1111\/jth.13491_bb0205","first-page":"36","volume":"20","author":"Hart","year":"2014","journal-title":"Hemophilia"},{"key":"10.1111\/jth.13491_bb0210","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.thromres.2014.12.018","article-title":"Enhanced pharmacokinetics of factor VIIa as a monomeric Fc fusion","volume":"135","author":"Salas","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13491_bb0215","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0220","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti\u2010TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennet","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/jth.13491_bb0230","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V126.23.551.551","article-title":"A subcutaneously administered investigational RNAi therapeutic (ALN\u2010AT3) targeting antithrombin for treatment of hemophilia: interim weekly and monthly dosing results in patients with hemophilia A and B. ASH Annual Meeting Abstract","volume":"126","author":"Pasi","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0235","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1111\/jth.13491_bb0240","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first\u2010in\u2010human phase 1 study of ACE910, a novel factor VIII\u2010mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0245","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2010mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13491_bb0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V76.2.345.345","article-title":"Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood","volume":"76","author":"Hantgan","year":"1990","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0255","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0260","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281031","article-title":"The International Society on Thrombosis and Haematosis von Willebrand disease database: an update","volume":"37","author":"Hampshire","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.13491_bb0265","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1538-7836.2006.01823.x","article-title":"Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD","volume":"4","author":"Eikenboom","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0270","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0275","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease (EUVWD)","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"key":"10.1111\/jth.13491_bb0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1008906103637","article-title":"Recombinant von Willebrand factor: potential therapeutic use","volume":"8","author":"Fischer","year":"1999","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl. 1","key":"10.1111\/jth.13491_bb0285","first-page":"S32","article-title":"Development of a plasma\u2010 and albumin\u2010free recombinant von Willebrand factor","volume":"29","author":"Turecek","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.13491_bb0290","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma\u2010free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0295","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13491_bb0300","first-page":"984","article-title":"Long\u2010term secondary prophylaxis in children, adolescents and young adults with Von Willebrand disease","volume":"104","author":"Halimeh","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0305","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of Von Willebrand's disease: results from the Von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0310","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","article-title":"Prophylaxis escalation in severe von Willebrand disease: a prospective study from the Von Willebrand Disease Prophylaxis Network","volume":"13","author":"Abshire","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1160\/TH10-01-0027","article-title":"A randomised pilot trial of the anti\u2010von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease","volume":"104","author":"Jilma","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0320","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","article-title":"The anti\u2010von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease","volume":"108","author":"Jilma\u2010Stohlawetz","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0325","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1538-7836.2012.04844.x","article-title":"Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0330","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline on behalf of the British Committee for Standards in Haematology","volume":"167","author":"Mumford","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13491_bb0335","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2516.2011.02635.x","article-title":"Efficacy of prophylaxis and genotype\u2013phenotype correlation in patients with severe factor X deficiency in Iran","volume":"18","author":"Karimi","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0340","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/hae.12894","article-title":"Pharmacokinetics of a high\u2010purity plasma\u2010derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency","volume":"22","author":"Austin","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1111\/jth.13491_bb0345","first-page":"38","article-title":"In vitro characterizations of the first therapeutic factor V concentrate, in development","volume":"12","author":"Lawrie","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13491_bb0350","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2516.2008.01695.x","volume":"14","author":"Keeling","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13491_bb0355","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-0033-1348948","article-title":"Congenital prothrombin deficiency: an update","volume":"39","author":"Lancellotti","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.13491_bb0360","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0022-2143(99)90062-8","article-title":"Clinical and laboratory manifestations of anti\u2010factor V antibodies","volume":"133","author":"Ortel","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1111\/jth.13491_bb0365","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650554","article-title":"Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use","volume":"76","author":"Nicolaisen","year":"1996","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.13491_bb0370","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1053\/j.seminhematol.2005.11.018","article-title":"Inhibitors to factor XI in patients with severe factor XI deficiency","volume":"43","author":"Salomon","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.13491_bb0375","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.85.1.232","article-title":"Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system","volume":"85","author":"Lorand","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.13491_bb0380","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/j.amepre.2009.12.023","article-title":"The universal data collection surveillance system for rare bleeding disorders","volume":"38","author":"Soucie","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1111\/jth.13491_bb0385","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0049-3848(10)70150-X","article-title":"EUHASS: The European Haemophilia Safety Surveillance system","volume":"127","author":"Makris","year":"2011","journal-title":"Thromb Res"},{"issue":"Suppl. S2","key":"10.1111\/jth.13491_bb0390","first-page":"162","article-title":"Antithrombin reduction improves coagulation in rare bleeding disorder plasma. Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis","volume":"13","author":"Sehgal","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13491","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622033906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622033906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13491\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:12:11Z","timestamp":1761534731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622033906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1538783622033906"],"URL":"https:\/\/doi.org\/10.1111\/jth.13491","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of bleeding disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}